Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of TY027 in healthy volunteers
NCT04429529Phase 1Completed
- Sponsor
- Tychan
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TY027 in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by Tychan. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 84 Days. Started Jun 2020; status: completed.
02
Drugs
TY027
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04429529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429529.